Summary
Other Scenarios:
- WYE - DNA
- WYE - COV
- DNA - TEVA
- COV - TEVA
| Buyer: | Wyeth (WYE) | Last Price: | 41.56 | Market Cap.: | 55.46B |
|---|---|---|---|---|---|
| Target: | Teva Pharmaceutical Industries Ltd (ADR) (TEVA) | Last Price: | 47.11 | Market Cap.: | 38.08B |
Lines of Business Summary:
- Wyeth (WYE) competes in 2 industries and 123 product/service groups
- Teva Pharmaceutical Industries Ltd (ADR) (TEVA) competes in 1 industry and 526 product/service groups
- A combined entity will have 5% Product/Service Group overlap
- Wyeth (WYE) has 5 and Teva Pharmaceutical Industries Ltd (ADR) (TEVA) has 0 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Consumer |
|
955 | |
Consumer Products and Services |
|
368 | |
|
Healthcare |
|
|
893 |
|
Biopharmaceuticals |
|
|
366 |
|
Medical Devices |
|
241 | |
|
Nutritional Health |
|
|
25 |
|
Outsourced Services |
|
66 | |
|
Veterinary Products and Services |
|
|
7 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 128)
|
Target (Total: 530)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 36)
|
Target (Total: 15)
|
Buyer (Total: 8)
|
Target (Total: 10)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 50,527 | 29,712 |
| Revenue Per Employee | 457,526.5 | 347,748.7 |
| Total Revenue | 5,763.5 | 2,576.0 |
| Total Expenses | 4,400.5 | 1,915.0 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
1,691.4 | 1,229.0 |
|
SG&A Expense
|
1,882.5 | 518.0 |
|
Research & Development
|
882.5 | 168.0 |
|
Other Operating Expense
|
-38.8 | 0.0 |
|
Operating Income
|
1,363.0 | 661.0 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
38.69 | 19.61 |
|
Fwd P/E
|
12.26 | 17.39 |
|
Fwd P/Rev
|
2.50 | 3.53 |
| Book Value | 18,210.5 | 13,724.0 |
|
Curr Portion of LTD/Cap Lease
|
311.6 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Wyeth is engaged in the discovery, development, manufacture, distribution and sale of a line of products in three primary businesses: Wyeth Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer Healthcare), and Fort Dodge Animal Health (Animal Health). Pharmaceuticals includes branded human ethical pharmaceuticals, biotechnology products, vaccines and nutrition products. Principal Pharmaceuticals products include neuroscience therapies, cardiovascular products, nutrition products, gastroenterology drugs, anti-infectives, vaccines, oncology therapies, musculoskeletal therapies, hemophilia treatments, immunological products and women?s healthcare products. Consumer Healthcare products include analgesics, cough/cold/allergy remedies, nutritional supplements, and hemorrhoidal, asthma and personal care items sold over-the-counter. Principal Animal Health products include vaccines, pharmaceuticals, parasite control and growth implants.
Target
Teva Pharmaceutical Industries Ltd. is a Global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories. The Company has an innovative pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson?s disease, as well as a proprietary specialty pharmaceutical business, which consists primarily of respiratory products. Teva?s active pharmaceutical ingredient (API) business sells to third-party manufacturers and provides vertical integration to Teva?s own pharmaceutical production. Teva?s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 50 countries, as well as 36 pharmaceutical manufacturing sites in 16 countries, 17 generic R&D centers operating mostly within certain manufacturing sites and 18 API manufacturing sites around the world. Teva Pharmaceutical Industries Ltd. is headquartered in Petach Tikva, Israel
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
71.81 | 51.84 |
|
Operating Margin %
|
28.82 | 25.46 |
|
Quick Ratio
|
2.32 | 1.2 |
|
Current Ratio
|
3.14 | 1.84 |
|
Coverage Ratio
|
0 | -0.02 |
| Total Assets | 42,717.3 | 23,412.0 |
| Return on Equity % | 25.35 | 14.25 |
| Return on Assets % | 10.81 | 8.35 |
|
Cash+ ST Inv. Per Share
|
9.83 | 3.45 |
| Total Debt | 11,804.5 | 5,188.0 |
| Total Debt to Equity % | 64.82 | 37.8 |
| Total Debt to Tangible Equity % | 86.21 | 152.68 |
|
Debt to Asset %
|
27.63 | 22.16 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
Consumer Products and Services |
|
|
|
Food, Beverage and Agriculture
Includes agricultural inputs like livestock and crops, as well as processed food and beverage products. Tobacco growers and cigarette manufacturers are also included.
|
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes medical devices that diagnose and treat eye disorders.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
Target Products:
|
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
Food, Beverage and Agriculture |
|
|
Agriculture |
|
|
|
Animal Production |
|
|
|
Support Activities for Animal Production
Includes food irradiation, animal feed, and other support activities.
Buyer Products:
|
|
|
|
Personal Care and Cleaning Products |
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Buyer Products:
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Adjunctive Treatments |
|
|
|
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Upper Respiratory |
|
|
|
Anticholinergic Agents
Therapeutics that treat allergic reactions by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Target Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Target Products:
|
|
|
|
Arrhythmia |
|
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Inotropic/Vasodilatory Agents
Therapeutics that treat acute heart failure by increasing intracellular ionized calcium and contractile force in cardiac muscle and relaxing vascular muscle.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat the ineffective pumping of the heart by acting on blood vessels to lower blood pressure.
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)/Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking alpha and beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the dopamine receptors of the heart muscle.
Target Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Target Products:
|
|
|
|
Hypotension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat low blood pressure by stimulating alpha adrenergic receptors.
Target Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Target Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that treat hypertension by increasing level of nitric oxide that help to dilate blood vessels.
Target Products:
|
|
|
|
Stroke |
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat hair loss by dilating blood vessels.
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Target Products:
|
|
|
|
Dermatitis |
|
|
|
Seborrheic (Dandruff) |
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Target Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Immunosuppressants
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by suppressing the immune system.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gall Bladder Disorders |
|
|
|
Cholelithiasis (Gallstones) |
|
|
|
Anticholelithic Agents
Therapeutics that treat gall stones by decreasing the liver's cholesterol synthesis and secretion.
Target Products:
|
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Ulcer Adhering Agents
Therapeutics that treat peptic ulcers by binding to it and protecting it from further damage.
Target Products:
|
|
|
|
Gastric |
|
|
|
Antisecretory Agents
Therapeutics that treat peptic ulcers by preventing the secretion of acid.
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Target Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroparesis |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Buyer Products:
Target Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Antiemetic Agents
Therapeutics that treat nausea or vomiting by acting locally on the hyperactive gastrointestinal wall.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
Target Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
Target Products:
|
|
|
|
Impacted Bowels |
|
|
|
Hyperosmotic Agents
Therapeutics that treat constipation by causing fluid overload, which in turn induces liquid stool within a short period of time.
Target Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Target Products:
|
|
|
|
Stool Softeners
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body.
Target Products:
|
|
|
|
Stool Softeners/Stimulants
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body as well as stimulating bowel contractions.
Target Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
Target Products:
|
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Target Products:
|
|
|
|
Stool Softeners/Stimulants
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body as well as stimulating bowel contractions.
Target Products:
|
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation associated with ulcerative colitis by preventing the accumulation of inflammatory cells like leukocytes and macrophages to the inflammation site.
Target Products:
|
|
|
|
Intestinal Intubation |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Buyer Products:
Target Products:
|
|
|
|
Rectal Disorders |
|
|
|
Hemorrhoids |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat hemorrhoids by stimulating the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat or suppress inflammation by preventing the accumulation of inflammatory cells like leucocytes and macrophages to the inflammation sites.
Buyer Products:
Target Products:
|
|
|
|
Stomatognathic Disorders |
|
|
|
Toothaches |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat toothache by numbing a localized area.
Target Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Target Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat hypertension by regulating the blood vessel dilation.
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.
Target Products:
|
|
|
|
Diabetic Neuropathy |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat diabetic neuropathy by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Target Products:
|
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Non-Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Target Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Cortisols
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Dexamethasones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Prednisones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Hypoglycemia |
|
|
|
Gluconeogenic Agents/Glycogenolytic Agents
Therapeutics that treat hypoglycemia by enabling the release of glucose from the liver.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Carnitine Deficiency |
|
|
|
Fatty Acid Transporters
Therapeutics that treat the depletion of long-chain fatty acids in the mitochondrial matrix by increasing carnitine level in the plasma, which facilitate the entry of long-chain fatty acids into the mitochondria.
Target Products:
|
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Target Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys and prevent the precipitation of urate in the joint.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce cholesterol levels by reducing the levels of low-density lipoproteins (LDL) and increasing levels of high-density lipoproteins (HDL).
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Target Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Somatostatin Analogs
Therapeutics that prevents the secretion of growth hormones.
Target Products:
|
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Target Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Target Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Hypoestrogenism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Estrogens/Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat menopause by a combination of natural female hormone and synthetic female hormone analogues.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat vasomotor symptoms associated with menopause by selectively preventing the removal of norepinephrine.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Hemophilia |
|
|
|
Hemophilia A |
|
|
|
Clotting Agents
Therapeutics that aid in blood coagulation.
Buyer Products:
|
|
|
|
Hemophilia B |
|
|
|
Clotting Agents
Therapeutics that assist in blood coagulation.
Buyer Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercalcemia |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat a disorder characterized by excessive calcium levels by inhibiting the resorption of bone.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds) |
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Target Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat hyperuricemia by preventing the conversion of hypoxanthine to uric acid.
Target Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Target Products:
|
|
|
|
Hypoglycemia |
|
|
|
Gluconeogenic Agents/Glycogenolytic Agents
Therapeutics that treat low blood sugar by promoting the breakdown of glycogen into glucose in the liver as well as the synthesis of glucose from non-carbohydrate precursors.
Target Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Target Products:
|
|
|
|
Potassium Supplements
Therapeutics that treat hypokalemia by providing potassium to the body.
Target Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Target Products:
|
|
|
|
Thrombocytopenia |
|
|
|
Platelet Growth Factors
Therapeutics that promote the growth of particular blood coagulating factors.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Psoriatic Arthritis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking the action of a pain mediator.
Target Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Discoid (DLE) |
|
|
|
Immunosuppressants
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques by inhibiting a full immune response.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques using a steroidal compound.
Target Products:
|
|
|
|
Systemic (SLE) |
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting the transformation of deoxyadenosine into deoxyinosine, thereby impairing the proliferation of certain white blood cells.
Target Products:
|
|
|
|
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Immunosuppressants
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by inhibiting a full immune response.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Glycylcyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes. This class of antibiotics is a group of tetracycline analogues developed to target tetracycline-resistant strains of bacteria.
Buyer Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Target Products:
|
|
|
|
Oxazolidinones
Therapeutics that treat a wide variety of infections by inhibiting early initiation of bacterial protein synthesis.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
Target Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
Target Products:
|
|
|
|
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gingivitis |
|
|
|
Chlorhexidines
Therapeutics that treat inflammation of the gums by causing leakage in bacterial cell walls.
Target Products:
|
|
|
|
Heliobacter pylori |
|
|
|
Proton Pump Inhibitors
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Periodontitis |
|
|
|
Tetracyclines
Therapeutics that treat bacterial infections of the gums, teeth, and underlying bone by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone/Joint Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections manifested in the bones or joints by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Conjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the clear membrane outside the eye preventing the mast cell release of histamine.
Target Products:
|
|
|
|
Keratitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea caused by bacterial infection by inhibiting the release of histamine and leukotrienes from mast cells.
Target Products:
|
|
|
|
Keratoconjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea and the clear membrane outside the eye caused by bacterial infection by blocking the release of histamines from mast cells.
Target Products:
|
|
|
|
Ocular Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.
Target Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Analgesics/Sodium Channel Blocking Agents
Therapeutics that treat pain associated with infection and inflammation of the middle ear space and ear drum by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Target Products:
|
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting an enzyme vital to bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Pharyngitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the cone shaped cavity at the back of the mouth caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Pneumonia |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat infections of the air passage caused by a wide variety of bacteria.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Tonsilitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lymphoid tissue on either side of the throat caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Tuberculosis |
|
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Target Products:
|
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Target Products:
|
|
|
|
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.
Target Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Combination |
|
|
|
Diphtheria/Tetanus (DT)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria and tetanus.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Ascariasis (Roundworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm.
Target Products:
|
|
|
|
Enterobiasis (Pinworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm. itching.
Target Products:
|
|
|
|
Hookworms |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the intestines.
Target Products:
|
|
|
|
Trichuriasis (Whipworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by large worms attached to the lining of the large intestine.
Target Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Target Products:
|
|
|
|
Tinea Barbae |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Tinea Capitis |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.
Target Products:
|
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Pedis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Unquium |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Tinea Versicolor |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the mucosa caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Target Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Sulfonamides
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Bone Fractures |
|
|
|
Growth Factor |
|
|
|
Recombinant Human Bone Morphogenetic Protein (rhBMP)
Therapeutics that induce the formation of bone and cartilage.
Buyer Products:
|
|
|
|
Osteoporosis |
|
|
|
Estrogens/Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by providing female hormones and other endocrine modulating substances which decrease the rate of bone loss.
Buyer Products:
|
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Target Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Target Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ankylosing spondylitis by blocking the effect of TNF-alpha, a pro-inflammatory molecule.
Buyer Products:
|
|
|
|
Fibromyalgia Syndrome (FMS) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Fibromyalgia Syndrome by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Target Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat inflammation by preventing the accumulation of Substance P at the inflammation sites.
Target Products:
|
|
|
|
Psoriatic Arthritis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking the action of a pain mediator.
Target Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Target Products:
|
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat Alzheimer's Disease by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Dementia |
|
|
|
Ergot Alkaloids
Therapeutics that treat dementia by blocking the alpha adrenergic receptors.
Target Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Target Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of sodium into nerve cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Grand Mal Seizures by preventing the entrance of sodium into nerve cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Target Products:
|
|
|
|
Status Epilepticus |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Target Products:
|
|
|
|
Headaches |
|
|
|
Chronic |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Tension Type |
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons and decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons as well as decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that prevent migraines by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation, as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Motion Sickness |
|
|
|
Anticholinergic Agents
Therapeutics that treat motion sickness by selectively deterring actions of the involuntary nervous system.
Target Products:
|
|
|
|
Antivertigo Agents
Therapeutics that prevent the sensation of motion.
Target Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.
Target Products:
|
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Target Products:
|
|
|
|
Trigeminal Neuralgia (Tic Douloureux) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat trigeminal Neuralgia by inhibiting the entrance of sodium into the nerve cells.
Target Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting the transformation of deoxyadenosine into deoxyinosine, thereby impairing the proliferation of certain white blood cells.
Target Products:
|
|
|
|
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.
Target Products:
|
|
|
|
Myasthenia Gravis (MG) |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Target Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Target Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Target Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the degradation of neurotransmitters.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by relaxing motor muscles and relieving pain.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Target Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by preventing the degradation of neurotransmitters.
Target Products:
|
|
|
|
Restless Leg Syndrome |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat Restless Leg Syndrome by stimulating dopamine activity.
Target Products:
|
|
|
|
Tourette`s Syndrome |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat the disorder involving uncontrolled verbal outbursts, ticks and facial expressions by blocking dopamine receptors on the neurons.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat obsessive compulsive disorder by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat panic disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat attention deficit disorder by blocking the dopamine receptors.
Target Products:
|
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Target Products:
|
|
|
|
Enuresis (Bedwetting) |
|
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Target Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat depression by blocking the dopamine receptors.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat depression by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Monoaminergic Antagonists/Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin as well as blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Target Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
Target Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Estrogens/Progestins
Therapeutics that treat premenstrual dysphoric disorders by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Target Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Target Products:
|
|
|
|
Serotonin/Dopamine Receptor Partial Agonists
Therapeutics that treat schizophrenia by enhancing activity in both serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat insomnia by preventing the functions of histamine on tissues as well as treating pain and suppressing fever.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prenatal/Postnatal Nutrition |
|
|
|
Multivitamins
Therapeutics that supplement the nutritional needs of women during pregnancy.
Target Products:
|
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
Target Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.
Buyer Products:
|
|
|
|
Dryness |
|
|
|
Estrogens
These are female sex hormones.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage breast cancers by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Target Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat breast cancer by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.
Target Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers by inhibiting the production of DNA but are not given with curative intent.
Target Products:
|
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Kaposi`s Sarcoma |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of spindle cells by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Malignant Melanoma |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Malignant Melanoma by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Target Products:
|
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancers of keratinizing epidermal cells by interacting with DNA.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal cancers without a curative intent by inhibiting the production of DNA.
Target Products:
|
|
|
|
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Target Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the stomach by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of the stomach by inhibiting the production of DNA.
Target Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage primary tumors of the pancreas by inhibiting the production of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Nitrosoureas
Therapeutics that can cross the blood-brain barrier to treat and manage pancreatic cancers by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage metastatic pancreatic cancer by inhibiting the production of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage pancreatic cancer without a curative intent by inhibiting the production of DNA.
Target Products:
|
|
|
|
Endocrinology |
|
|
|
Carcinoid Tumors |
|
|
|
Palliative Agents |
|
|
|
Somatostatin Analogs
Therapeutics that treat and manage a serotonin secreting neoplasm known as a carcinoid tumor by inhibiting the secretion of growth hormone which allows the tumor to grow rapidly.
Target Products:
|
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the thyroid gland by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the head and neck by interacting with DNA.
Target Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of immature lymphocytic cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Lymphocytic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics isolated principally from microorganisms that treat rapidly progressing cancers of lymphocytic cells by interacting with DNA.
Target Products:
|
|
|
|
Chronic |
|
|
|
Lymphocytic (CLL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.
Target Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Erythroleukemic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Monocytic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mononuclear cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Myeloblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of myelogenous cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.
Target Products:
|
|
|
|
Monoclonal Antibodies/Antitumor Antibiotics
Therapeutics that use monoclonal antibodies to deliver chemotherapeutic agents isolated principally from microorganisms that treat rapidly progressing cancers of myelogenous cells by interacting with DNA.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Promyelocytic (APL) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Chronic |
|
|
|
Granulocytic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of myelocytic cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Myeloblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of immature myeloid cells by inhibiting the production of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy by preventing the formation of uric acid from xanthine.
Target Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Cutaneous T-Cell (CTCL) |
|
|
|
Mycosis Fungoides |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage T-Cell lymphomas of the skin by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Hodgkin`s Disease |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Hodgkin's Disease by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Target Products:
|
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy for lymphoma characterized by the presence of Reed-Sternberg cells by preventing the formation of uric acid from xanthine.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting signals required for cell cycle progression, cell growth, and proliferation.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphomas of B-cells and T-cells by interacting with DNA.
Target Products:
|
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mature antibody producing white blood cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Osteosarcoma |
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Osteolytic Bone Metastases |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.
Target Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Neuroblastoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of primitive ganglion cells by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a and manage cancer of primitive ganglion cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Opthalmology |
|
|
|
Retinoblastoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of the retina by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by inhibiting the production of DNA.
Target Products:
|
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary malignanat tumors of the cervix by interacting with DNA.
Target Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by by inhibiting signals required for cell cycle progression, cell growth, and proliferation.
Buyer Products:
|
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage tumors of the kidney by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage ovarian cancer by inhibiting the production of DNA.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Germ Cell Tumors |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage ovarian cancer by inhibiting the production of DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers by interacting with DNA and inhibiting cell division but are not curative.
Target Products:
|
|
|
|
Penile Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the squamous cells of the penis by interacting with DNA.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.
Buyer Products:
|
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations but are not curative.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.
Target Products:
|
|
|
|
Testicular Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage primary tumors of the testes by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the testes by interacting with DNA.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage testicular cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the testes by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Papillocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage mushroom shaped tumors that arise from the inner lining of the bladder by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Transitional Cell Carcinoma |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancers arising from the lining of the bladder by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers arising from the lining of the bladder by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers that arise from skin cells of the external female genitalia by interacting with DNA.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Dry Eye |
|
|
|
Lubricants
Therapeutics that wet the eye and lubricate the eye.
Target Products:
|
|
|
|
Glaucoma |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that prevent inflammation by counteracting the histamine protein and by preventing fluid congestion.
Target Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Target Products:
|
|
|
|
Primary |
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Target Products:
|
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Target Products:
|
|
|
|
Local |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
Target Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Target Products:
|
|
|
|
Analgesics/Antipyretics/Antihistamines
Therapeutics that treat fever and pain by inhibiting the action of prostaglandins, as well as suppressing inflammation.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat pain by inhibiting the reuptake of GABA, which increases the levels of GABA in the synapses.
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially, as well as prevent inflammation by inhibiting the action of prostaglandins.
Buyer Products:
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat pain by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain by inhibiting the accumulation of Substance P at the inflammation site.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.
Target Products:
|
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Complications |
|
|
|
Bacterial Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Agonists/Anticholinergic Agents
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine and by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Target Products:
|
|
|
|
Emphysema |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
Target Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
Target Products:
|
|
|
|
Decongestants/Analgesics
Therapeutics that treat coughs and colds by reducing mucous build up and relieving pain.
Buyer Products:
|
|
|
|
Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, relieving pain, and reducing fever.
Target Products:
|
|
|
|
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and helping in the ejection of the mucous.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Buyer Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Target Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Buyer Products:
Target Products:
|
|
|
|
Surgery |
|
|
|
Digestive System |
|
|
|
Post-Operative Ileus/Constipation |
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent post surgical nausea and vomiting through a combination of blocking neurotransmitters and gastrointestinal movement stimulants.
Target Products:
|
|
|
|
Neuromuscular Blockage |
|
|
|
Cholinesterase Inhibitors
Therapeutics that reverse neuromuscular blockage by inhibiting the break down of acetylcholine.
Target Products:
|
|
|
|
Urinary Retention |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat urinary retention by preventing the breakdown of acetylcholine resulting in the increased body secretions.
Target Products:
|
|
|
|
Neurology |
|
|
|
Seizures |
|
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Target Products:
|
|
|
|
Toxicology |
|
|
|
Animal Poisoning |
|
|
|
Snakes |
|
|
|
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.
Buyer Products:
|
|
|
|
Heavy Metal Poisoning |
|
|
|
Chelating Agents |
|
|
|
Iron
Therapeutics that form chemical complexes with iron and are subsequently excreted.
Target Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Antihistamines
Therapeutics that treat alcohol withdrawal by blocking the H2 receptors and thus the effects of histamines.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Transplantation |
|
|
|
Heart |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
Target Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that increase blood flow in the penis by dilating blood vessels.
Target Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Target Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat puberty disorders by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Cystitis |
|
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Target Products:
|
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat diabetes induced kidney diseases by inhibiting a certain enzyme necessary for regulation of blood pressure.
Target Products:
|
|
|
|
Nephrolithiasis/Renal Calculi (Kidney Stones) |
|
|
|
Calcium |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat the formation of kidney stones from calcium deposits by reducing uric acid formation through the inhibition of xanthine oxidase.
Target Products:
|
|
|
|
Uric Acid |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the conversion of hypoxanthine to uric acid, thus preventing the deposition of excess uric acid in the kidneys.
Target Products:
|
|
|
|
Renal Insufficiency |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that delay or treat kidney disease by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Anorexia (Appetite Loss) |
|
|
|
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.
Target Products:
|
|
|
|
Cachexia |
|
|
|
Progestins
Therapeutics that treat cachexia by providing female hormones.
Target Products:
|
|
|
|
Obesity |
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Target Products:
|
|
|
|
Wound Management |
|
|
|
Bone Fractures |
|
|
|
Growth Factors |
|
|
|
Recombinant Human Bone Morphogenetic Proteins (rhBMP)
Therapeutics that promote healing of a broken bone by promoting the proliferation of bone cells.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery |
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Metered Dose |
|
|
|
Dry Powder |
|
|
|
Inhalers (DPI)
Mouthpiece-type of medical devices from which the patients inhale the medication mixture
Target Products:
|
|
|
|
Liquid |
|
|
|
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Treatment |
|
|
|
Dry Eye |
|
|
|
Lubricants
Devices used to alleviate low level of moisture in eye tissue by adding fluid.
Target Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Target Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
Children`s Health
Products consisting of dietary/naturopathic supplements that are intended to support infants and children's health.
Target Products:
|
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
Target Products:
|
|
|
|
Men`s Health
Products consisting of dietary/naturopathic supplements that are intended to support men's health.
Target Products:
|
|
|
|
Sports Performance/Energy
Products consisting of dietary/naturopathic supplements that are intended to enhance energy level and athletic performance.
Target Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Buyer Products:
Target Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Target Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Target Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Target Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
Target Products:
|
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Biogen Idec Inc.
|
|
n/a | 19,059.016 | 29.91 | 19.43 | 6.01 | 5.08 | 10.01 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,537.808 | 43.15 | 15.38 | 2.21 | 1.93 | 57.12 | |
|
APP Pharmaceuticals, Inc.
|
|
n/a | 2,101.996 | 61.19 | 15.27 | 3.25 | 1.87 | n/a | |
|
XenoPort, Inc.
|
|
n/a | 1,090.321 | 38.67 | -27.95 | 9.58 | 19.34 | 8.69 | |
|
Impax Laboratories Inc.
|
|
n/a | 526.362 | 450.59 | 9.34 | 4.67 | n/a | 8.97 | |
|
Pain Therapeutics, Inc.
|
|
n/a | 380.159 | 18.72 | 17.87 | 5.76 | 5.99 | 3.66 | |
|
MiddleBrook Pharmaceuticals, Inc.
|
|
n/a | 238.296 | 0.00 | -9.74 | 22.78 | n/a | n/a | |
|
DepoMed, Inc.
|
|
n/a | 168.969 | 3.48 | n/a | 2.58 | 6.03 | 3.71 | |
|
Spectrum Pharmaceuticals, Inc.
|
|
n/a | 77.772 | 0.00 | -1.75 | 10.14 | 7.46 | 1.60 | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 186,001.375 | 17.59 | 14.73 | 3.04 | 2.90 | 12.78 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 163,455.599 | 16.51 | 19.02 | 3.49 | 3.93 | 5.01 | |
| Target | |||||||||
|
Genentech, Inc.
|
|
n/a | 83,975.381 | 30.33 | 25.13 | 7.16 | 6.40 | 9.17 | |
|
Covidien Ltd.
|
|
n/a | 22,752.866 | 0.00 | 18.60 | 2.20 | 2.33 | n/a | |
|
Genzyme Corporation
|
|
n/a | 20,272.859 | 42.22 | 21.49 | 5.32 | 4.37 | 5.55 | |
|
Biogen Idec Inc.
|
|
n/a | 19,059.016 | 29.91 | 19.43 | 6.01 | 5.08 | 10.01 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 10,231.324 | 0.00 | -50.69 | 13.47 | 9.42 | n/a | |
|
Hospira, Inc.
|
|
n/a | 6,826.852 | 49.92 | 17.22 | 1.99 | 1.86 | n/a | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,537.808 | 43.15 | 15.38 | 2.21 | 1.93 | 57.12 | |
|
Cephalon, Inc.
|
|
n/a | 4,451.444 | 0.00 | 14.72 | 2.51 | 2.33 | 576.31 | |
|
Mylan Inc.
|
|
n/a | 3,753.734 | 0.00 | 23.06 | 1.41 | 0.78 | n/a | |
|
Perrigo Company
|
|
n/a | 3,674.814 | 35.29 | 24.29 | 2.36 | 2.08 | 8.92 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 3,033.021 | 21.51 | 14.87 | 1.21 | 1.17 | 8.21 | |
|
Dr. Reddy's Laboratories Limited (ADR)
|
|
n/a | 2,527.079 | 14.51 | 22.51 | 1.90 | 2.01 | n/a | |
|
APP Pharmaceuticals, Inc.
|
|
n/a | 2,101.996 | 61.19 | 15.27 | 3.25 | 1.87 | n/a | |
|
Alpharma Inc.
|
|
n/a | 1,480.206 | 0.00 | 111.46 | 2.05 | 2.05 | 4.07 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Impax Laboratories Inc.
|
|
n/a | 526.362 | 450.59 | 9.34 | 4.67 | n/a | 8.97 | |
|
Ness Technologies, Inc.
|
|
n/a | 379.050 | 37.57 | 9.54 | 0.67 | 0.60 | 4.18 | |
|
Pharsight Corporation
|
|
n/a | 44.881 | 0.00 | 31.25 | 1.60 | 1.67 | 5.10 | |
| Buyer | |||||||||
|
etrials Worldwide, Inc.
|
|
18.40% | 19.278 | 0.00 | -9.20 | 0.86 | 0.85 | 1.11 | |
|
Curis, Inc.
|
|
16.00% | 91.067 | 0.00 | n/a | 5.56 | n/a | 2.41 | |
|
Exelixis, Inc.
|
|
14.00% | 814.323 | 0.00 | -4.97 | 7.18 | 6.64 | 96.98 | |
|
Trubion Pharmaceuticals, Inc.
|
|
12.00% | 145.689 | 0.00 | -4.77 | 7.23 | 7.09 | 2.73 | |
|
Martek Biosciences Corp.
|
|
10.00% | 1,057.525 | 27.88 | 31.05 | 3.31 | 3.05 | 2.25 | |
|
Accenture Ltd.
|
|
n/a | 27,313.598 | 18.84 | 13.99 | 1.17 | 1.18 | 20.87 | |
|
WPP Group plc (ADR)
|
|
n/a | 14,717.725 | 16.89 | 12.95 | 1.25 | 1.10 | n/a | |
| Target | |||||||||
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 3,033.021 | 21.51 | 14.87 | 1.21 | 1.17 | 8.21 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Manhattan Associates, Inc.
|
|
n/a | 560.119 | 18.21 | 17.73 | 1.66 | 1.52 | 4.93 | |
|
Impax Laboratories Inc.
|
|
n/a | 526.362 | 450.59 | 9.34 | 4.67 | n/a | 8.97 | |
|
Ness Technologies, Inc.
|
|
n/a | 379.050 | 37.57 | 9.54 | 0.67 | 0.60 | 4.18 | |
|
I-Many, Inc.
|
|
n/a | 123.693 | 0.00 | -50.00 | 3.05 | 2.62 | n/a | |
|
BioSante Pharmaceuticals, Inc.
|
|
n/a | 116.356 | 0.00 | -7.29 | 236.45 | 89.92 | 3.91 | |
|
Compugen Ltd. (USA)
|
|
n/a | 67.834 | 0.00 | n/a | 374.19 | n/a | 3.99 | |
|
Antares Pharma, Inc.
|
|
n/a | 62.655 | 0.00 | -5.33 | 7.98 | 11.32 | 3.96 | |
|
Magic Software Enterprises Ltd.
|
|
n/a | 54.503 | 4.32 | n/a | 0.93 | n/a | 1.20 | |
|
Pharsight Corporation
|
|
n/a | 44.881 | 0.00 | 31.25 | 1.60 | 1.67 | 5.10 | |
|
Genelabs Technologies
|
|
n/a | 38.498 | 0.00 | -2.28 | 2.28 | 6.42 | 1.18 | |
|
AutoImmune Inc.
|
|
n/a | 29.749 | 0.00 | n/a | 101.27 | n/a | 3.37 | |
|
Ambrilia Biopharma Inc.
|
|
n/a | 21.584 | 0.00 | n/a | 26.54 | n/a | 2.93 | |
|
Procognia Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
| Buyer | |||||||||
|
Medtronic, Inc.
|
|
n/a | 55,758.291 | 25.00 | 19.22 | 4.31 | 4.11 | 47.29 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Sciele Pharma Inc.
|
|
n/a | 737.027 | 16.23 | 10.32 | 1.93 | 1.68 | 85.38 | |
|
MWI Veterinary Supply, Inc.
|
|
n/a | 452.332 | 26.65 | 22.94 | 0.60 | 0.54 | 3.53 | |
|
Trubion Pharmaceuticals, Inc.
|
|
n/a | 145.689 | 0.00 | -4.77 | 7.23 | 7.09 | 2.73 | |
|
Columbia Laboratories Inc.
|
|
n/a | 116.394 | 0.00 | n/a | 3.93 | n/a | n/a | |
|
Neurogen Corporation
|
|
n/a | 96.299 | 0.00 | -1.94 | 6.24 | 36.49 | 1.76 | |
|
DOV Pharmaceutical, Inc.
|
|
n/a | 7.753 | 0.57 | n/a | 0.25 | n/a | 0.68 | |
| Target | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Alcon, Inc.
|
|
n/a | 44,185.051 | 27.85 | 23.07 | 7.89 | 6.91 | 16.62 | |
|
Baxter International Inc.
|
|
n/a | 37,733.634 | 22.11 | 18.57 | 3.35 | 3.08 | 7.23 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,537.808 | 43.15 | 15.38 | 2.21 | 1.93 | 57.12 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
XenoPort, Inc.
|
|
n/a | 1,090.321 | 38.67 | -27.95 | 9.58 | 19.34 | 8.69 | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 591.924 | 11.86 | 22.97 | 0.77 | 0.94 | 1.75 | |
|
Novacea, Inc.
|
|
n/a | 70.665 | 0.00 | -3.31 | 4.24 | n/a | 1.54 | |
|
Sonus Pharmaceuticals, Inc.
|
|
n/a | 15.560 | 0.00 | -0.66 | 0.77 | n/a | 0.49 | |
|
H. Lundbeck A/S
|
|
n/a | 0.000 | 0.00 | n/a | 0.00 | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Cephalon, Inc.
|
|
n/a | 4,451.444 | 0.00 | 14.72 | 2.51 | 2.33 | 576.31 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Impax Laboratories Inc.
|
|
n/a | 526.362 | 450.59 | 9.34 | 4.67 | n/a | 8.97 | |
|
Indevus Pharmaceuticals
|
|
n/a | 356.326 | 0.00 | -6.23 | 5.14 | 4.24 | n/a | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 186,001.375 | 17.59 | 14.73 | 3.04 | 2.90 | 12.78 | |
|
Abbott Laboratories
|
|
n/a | 84,768.268 | 23.51 | 16.99 | 3.27 | 2.97 | 43.94 | |
| Target | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Wyeth
|
|
n/a | 55,458.079 | 12.01 | 12.26 | 2.48 | 2.50 | 4.05 | |
|
Alcon, Inc.
|
|
n/a | 44,185.051 | 27.85 | 23.07 | 7.89 | 6.91 | 16.62 | |
|
Baxter International Inc.
|
|
n/a | 37,733.634 | 22.11 | 18.57 | 3.35 | 3.08 | 7.23 | |
|
Eisai Co., Ltd (ADR)
|
|
n/a | 9,903.066 | 13.89 | 13.80 | 1.50 | 1.36 | 2.34 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,537.808 | 43.15 | 15.38 | 2.21 | 1.93 | 57.12 | |
|
Cephalon, Inc.
|
|
n/a | 4,451.444 | 0.00 | 14.72 | 2.51 | 2.33 | 576.31 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 3,033.021 | 21.51 | 14.87 | 1.21 | 1.17 | 8.21 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Alpharma Inc.
|
|
n/a | 1,480.206 | 0.00 | 111.46 | 2.05 | 2.05 | 4.07 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 1,153.591 | 0.00 | -15.91 | 82.27 | 168.18 | 8.30 | |
|
XenoPort, Inc.
|
|
n/a | 1,090.321 | 38.67 | -27.95 | 9.58 | 19.34 | 8.69 | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 591.924 | 11.86 | 22.97 | 0.77 | 0.94 | 1.75 | |
|
Impax Laboratories Inc.
|
|
n/a | 526.362 | 450.59 | 9.34 | 4.67 | n/a | 8.97 | |
|
Indevus Pharmaceuticals
|
|
n/a | 356.326 | 0.00 | -6.23 | 5.14 | 4.24 | n/a | |
|
Bentley Pharmaceuticals, Inc.
|
|
n/a | 349.993 | 130.38 | 34.87 | 2.81 | 2.55 | 3.52 | |
|
Protalix BioTherapeutics Inc.
|
|
n/a | 199.505 | 0.00 | -10.11 | n/a | 5.15 | 3.13 | |
|
ImmunoGen, Inc.
|
|
n/a | 156.613 | 0.00 | -5.42 | 3.96 | 3.96 | 2.95 | |
|
BioSante Pharmaceuticals, Inc.
|
|
n/a | 116.356 | 0.00 | -7.29 | 236.45 | 89.92 | 3.91 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 22,399.8 | 9,408.0 | 31,807.8 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 22,399.8 | 9,408.0 | 31,807.8 |
|
Cost of Revenue
|
6,313.7 | 4,531.0 | 10,844.7 |
|
SG&A Expense
|
6,753.7 | 1,901.0 | 8,654.7 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
3,256.8 | 581.0 | 3,837.8 |
|
Interest Expense
|
-90.5 | 0.0 | -90.5 |
|
Other Operating Expense
|
-290.5 | 0.0 | -290.5 |
| Total Expenses | 15,943.1 | 7,013.0 | 22,956.1 |
|
Operating Income
|
6,456.7 | 2,395.0 | 8,851.7 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
0.0 | -42.0 | -42.0 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | 6,456.7 | 2,353.0 | 8,809.7 |
| Income Taxes | 1,840.7 | 397.0 | 2,237.7 |
| Income After Taxes | 4,616.0 | 1,956.0 | 6,572.0 |
| Minority Interest (IS) | 0.0 | -1.0 | -1.0 |
| Equity in Affiliates | 0.0 | -3.0 | -3.0 |
|
Net Income - Excl. Xord. Items
|
4,616.0 | 1,952.0 | 6,568.0 |
|
Net Income - Incl. Xord. Items
|
4,616.0 | 1,952.0 | 6,568.0 |
| Preferred Dividends | -0.0 | 0.0 | -0.0 |
|
Income Avail. to Common
|
4,615.9 | 1,952.0 | 6,567.9 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
1,338.6 | 774.0 | 2,112.6 |
|
Basic EPS - Excl. Xord. Items
|
3.45 | 2.52 | 3.11 |
|
Basic EPS - Incl. Xord. Items
|
3.45 | 2.52 | 3.11 |
| Full Dilution Adjustment | 8.5 | 4.0 | 12.5 |
| Fully Diluted Shares Outstanding | 1,367.9 | 834.0 | 2,201.9 |
|
F.D. EPS - Excl. Xord. Items
|
3.37 | 2.34 | 2.98 |
|
F.D. EPS - Incl. Xord. Items
|
3.37 | 2.34 | 2.98 |
| Dividends Per Common Share | 1.08 | 0.42 | 1.50 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
10,453.9 | 1,488.0 | 11,941.9 |
|
ST Investments
|
2,993.8 | 1,387.0 | 4,380.8 |
|
Accounts Receivable
|
3,528.0 | 3,546.0 | 7,074.0 |
|
Inventory
|
3,035.4 | 2,440.0 | 5,475.4 |
|
Prepayments and Advances
|
0.0 | 998.0 | 998.0 |
|
Other Current Assets
|
2,972.5 | 0.0 | 2,972.5 |
|
Current Assets
|
22,983.6 | 9,859.0 | 32,842.6 |
|
PPE
|
16,221.2 | 0.0 | 16,221.2 |
|
Accum D&A
|
-5,149.0 | 0.0 | -5,149.0 |
|
PPE, Net
|
11,072.2 | 2,515.0 | 13,587.2 |
| Goodwill & Intangibles | 4,518.6 | 10,326.0 | 14,844.6 |
| Long Term Investments | 0.0 | 632.0 | 632.0 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
4,143.0 | 80.0 | 4,223.0 |
| Total Assets | 42,717.3 | 23,412.0 | 66,129.3 |
| Liabilities | |||
| Accounts Payable | 1,268.6 | 1,383.0 | 2,651.6 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 5,333.5 | 0.0 | 5,333.5 |
|
ST Debt
|
0.0 | 1,841.0 | 1,841.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
311.6 | 0.0 | 311.6 |
| Other (Current) Liabilities | 410.6 | 2,147.0 | 2,557.6 |
|
Current Liab.
|
7,324.3 | 5,371.0 | 12,695.3 |
|
LT Debt
|
11,492.9 | 3,347.0 | 14,839.9 |
|
Total LT Debt
|
11,492.9 | 3,347.0 | 14,839.9 |
| Minority Interest (BS) | 0.0 | 36.0 | 36.0 |
| Deferred Taxes | 0.0 | 459.0 | 459.0 |
|
Other LT Liab.
|
5,689.6 | 475.0 | 6,164.6 |
|
Total Liabilities
|
24,506.7 | 9,688.0 | 34,194.7 |
| Shareholders Equity | |||
| Preferred Stock | 0.0 | 0.0 | 0.0 |
| Common Stock | 445.9 | 46.0 | 491.9 |
| Additional Paid in Capital | 7,125.5 | 8,254.0 | 15,379.5 |
| Retained Earnings | 10,417.6 | 5,041.0 | 15,458.6 |
| Treasure Stock | 0.0 | -982.0 | -982.0 |
| Other Equity | 221.4 | 1,365.0 | 1,586.4 |
|
Total Equity
|
18,210.5 | 13,724.0 | 31,934.5 |
|
Total Liab. & Equity
|
42,717.3 | 23,412.0 | 66,129.3 |
|
Shares Outstanding
|
1,337.8 | 808.0 | 2,145.8 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 4,616.0 | 1,952.0 | 6,568.0 |
| CF Depreciation | 842.7 | 521.0 | 1,363.7 |
| CF Amortization | 76.0 | 0.0 | 76.0 |
| CF Deferred Taxes | 756.7 | 111.0 | 867.7 |
| Other Non-Cash Items | -165.9 | 67.0 | -98.9 |
| Change in Working Capital | -249.8 | -838.0 | -1,087.8 |
| Total Cash From Operating Activities | 5,875.7 | 1,813.0 | 7,688.7 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,390.7 | -542.0 | -1,932.7 |
| Other Investing Cash Flows | -1,211.7 | -811.0 | -2,022.7 |
| Total Cash From Investing Activities | -2,602.3 | -1,353.0 | -3,955.3 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -1,423.5 | -299.0 | -1,722.5 |
| Purchase Or Sale of Stock | -599.8 | 212.0 | -387.8 |
| Purchase and Retirement of Debt | -5.7 | -158.0 | -163.7 |
| Other Financing Cash Flow | 0.0 | -117.0 | -117.0 |
| Total Cash From Financing Activities | 350.1 | -362.0 | -11.9 |
| Exchange Rate Effects | 52.1 | 58.0 | 110.1 |
| Net Change in Cash | 3,675.6 | 156.0 | 3,831.6 |
| Cash Taxes Paid | 1,138.7 | 197.0 | 1,335.7 |
| Cash Interest Paid | 642.5 | 179.0 | 821.5 |